Heska (HSKA) Getting Somewhat Positive Press Coverage, Accern Reports
News headlines about Heska (NASDAQ:HSKA) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Heska earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 45.3923330538859 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s analysis:
- Heska promotes Catherine Grassman to company VP, CAO and controller (innovationews.com)
- Heska (HSKA) Earns “Buy” Rating from Raymond James Financial (americanbankingnews.com)
- Analysts Anticipate Heska Corp (HSKA) Will Announce Quarterly Sales of $41.14 Million (americanbankingnews.com)
- Tiverton Asset Management Lowered By $769,998 Its Heska (HSKA … – Hill Country Times (hillcountrytimes.com)
- Heska promotes Catherine Grassman to Vice President and Chief … – Markets Insider (markets.businessinsider.com)
A number of equities analysts recently commented on the company. Raymond James Financial reaffirmed a “buy” rating on shares of Heska in a report on Monday. Zacks Investment Research cut Heska from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. BidaskClub cut Heska from a “buy” rating to a “hold” rating in a report on Monday, August 14th. B. Riley decreased their target price on Heska from $96.50 to $93.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. Finally, Canaccord Genuity assumed coverage on Heska in a report on Thursday, October 5th. They issued a “buy” rating and a $115.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $113.30.
Heska (NASDAQ:HSKA) last announced its earnings results on Thursday, November 2nd. The medical research company reported $0.40 EPS for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.03. Heska had a return on equity of 15.35% and a net margin of 10.67%. The company had revenue of $31.40 million for the quarter, compared to analysts’ expectations of $36.10 million. During the same period last year, the firm earned $0.45 EPS. Heska’s revenue for the quarter was down 6.0% compared to the same quarter last year. research analysts anticipate that Heska will post 2.03 EPS for the current fiscal year.
In other Heska news, insider Michael J. Mcginley sold 7,826 shares of the stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total value of $681,957.64. Following the completion of the sale, the insider now owns 106,771 shares in the company, valued at approximately $9,304,024.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 14.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Heska (HSKA) Getting Somewhat Positive Press Coverage, Accern Reports” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/08/heska-hska-getting-somewhat-positive-press-coverage-accern-reports.html.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Stock Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related stocks with our FREE daily email newsletter.